March 18 (Reuters) - The U.S. Food and Drug Administration said on Monday it had approved UK-based Orchard Therapeutics' gene therapy for the treatment of children with a rare hereditary disease called metachromatic leukodystrophy (MLD). (Reporting by Mariam Sunny in Bengaluru; Editing by Sriraj Kalluvila)
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2,726 JPY | -0.04% | +0.68% | +15.04% |
Jun. 05 | Kyowa Kirin Repurchases 3.3 Million Shares in May | MT |
May. 07 | Kyowa Kirin's Profit Up 15% in Q1 | MT |
Stocks mentioned in the article
Price
|
Change
|
5d. change
|
Capi.
| ||
---|---|---|---|---|---|
2,777 PTS | -0.20% | -0.38% | - | ||
2,726 JPY | -0.04% | +0.68% | 9.2B | ||
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+15.04% | 9.2B | |
+19.01% | 80.29B | |
-18.33% | 4.67B | |
+43.39% | 4.49B | |
+13.95% | 4.27B | |
+10.46% | 2.25B | |
-28.40% | 2.13B | |
+15.93% | 2.1B | |
-43.17% | 1.78B | |
-0.50% | 1.64B |
- Stock Market
- Equities
- 4151 Stock
- News Kyowa Kirin Co. Ltd.
- US approves first gene therapy for rare genetic disease